Molecular biomarkers in prostate cancer

Bibliography

• Flaig TW, Nordeen SK, Lucia MS, et al. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol 2007;177:1229-37
   PubMed Web of Science ®Google Scholar
• Gutman AB, Gutman EB. An ‘Acid’ phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938;17:473-8
   PubMedGoogle Scholar
• Gutman AB. The development of the acid phosphatase test for prostatic carcinoma: the Sixth Ferdinand C. Valentine Memorial Lecture. Bull N Y Acad Med 1968;44:63-76
   PubMedGoogle Scholar
• Taira A, Merrick G, Wallner K, Dattoli M. Reviving the acid phosphatase test for prostate cancer. Oncology (Williston Park) 2007;21:1003-10
   PubMed Web of Science ®Google Scholar
• Saito T, Hara N, Kitamura Y, Komatsubara S. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Urology 2007;70:702-5
   PubMed Web of Science ®Google Scholar
• Fang LC, Dattoli M, Taira A, et al. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology 2008;71:146-50
   PubMed Web of Science ®Google Scholar
• Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int 2008;101:5-10
   PubMed Web of Science ®Google Scholar
• Battikhi MN, Hussein I. Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. Int Urol Nephrol 2006;38:559-64
   PubMed Web of Science ®Google Scholar
• Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73
   PubMed Web of Science ®Google Scholar
• Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008;101:809-16
   PubMed Web of Science ®Google Scholar
• Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1679-84
   PubMed Web of Science ®Google Scholar
• Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist 2008;13:299-305
   PubMed Web of Science ®Google Scholar
• Antenor JA, Roehl KA, Eggener SE, et al. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005;66:156-60
   PubMed Web of Science ®Google Scholar
• Zhu H, Roehl KA, Antenor JA, Catalona WJ. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 2005;66:547-51
   PubMed Web of Science ®Google Scholar
• Grubb RL III, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008;102:1524-30
   PubMed Web of Science ®Google Scholar
• Schroder FH. Screening for prostate cancer (PC)Őan update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 2008;26:533-41
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24
   PubMed Web of Science ®Google Scholar
• Stamey TA, Caldwell M, Mcneal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301
   PubMed Web of Science ®Google Scholar
• Steuber T, O‘Brien MF, Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 2008;54:31-40
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56:255-60
   PubMed Web of Science ®Google Scholar
• Bradford TJ, Tomlins SA, Wang X, Chinnaiyan AM. Molecular markers of prostate cancer. Urol Oncol 2006;24:538-51
   PubMed Web of Science ®Google Scholar
• Steuber T, Helo P, Lilja H. Circulating biomarkers for prostate cancer. World J Urol 2007;25:111-9
   PubMed Web of Science ®Google Scholar
• Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8
   PubMed Web of Science ®Google Scholar
• Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008;11:112-20
   PubMed Web of Science ®Google Scholar
• D‘Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35
   PubMed Web of Science ®Google Scholar
• D‘Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7
   PubMed Web of Science ®Google Scholar
• Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 2006;176:1399-403
   PubMed Web of Science ®Google Scholar
• Loeb S, Roehl KA, Nadler RB, et al. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol 2007;178:2348,52; discussion 2352-3
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008;101:675-83
   PubMed Web of Science ®Google Scholar
• Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006;67:762-8
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170:2181-5
   PubMed Web of Science ®Google Scholar
• Lein M, Semjonow A, Graefen M, et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 2005;174:2150-3
   PubMed Web of Science ®Google Scholar
• Steuber T, Nurmikko P, Haese A, et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002;168:1917-22
   PubMed Web of Science ®Google Scholar
• Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007;43:1918-26
   PubMed Web of Science ®Google Scholar
• Alapont Alacreu JM, Navarro Rosales S, Budia Alba A, et al. PSA and hK2 in the diagnosis of prostate cancer. Actas Urol Esp 2008;32:575-88
   PubMed Web of Science ®Google Scholar
• Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999;45:1960-6
   PubMed Web of Science ®Google Scholar
• Raaijmakers R, de Vries SH, Blijenberg BG, et al. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol 2007;52:1358-64
   PubMed Web of Science ®Google Scholar
• Mohammed AA, Shergill IS, Vandal MT, Gujral SS. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn 2007;7:345-9
   PubMed Web of Science ®Google Scholar
• Grasso YZ, Gupta MK, Levin HS, et al. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998;58:1456-9
   PubMed Web of Science ®Google Scholar
• Adsan O, Cecchini MG, Bisoffi M, et al. Can the reverse transcriptase-polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen improve staging and predict biochemical recurrence? BJU Int 2002;90:579-85
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang CY, Yang R, et al. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. Urol Oncol 2008;26:634-640
   PubMed Web of Science ®Google Scholar
• Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69:714-20
   PubMed Web of Science ®Google Scholar
• Berruti A, Mosca A, Porpiglia F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007;178:838,43; quiz 1129
   PubMed Web of Science ®Google Scholar
• Hirano D, Minei S, Sugimoto S, et al. Implications of circulating chromogranin A in prostate cancer. Scand J Urol Nephrol 2007;41:297-301
   PubMed Web of Science ®Google Scholar
• Sciarra A, Gentile V, Monti S, et al. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int 2008;80:68-73
   PubMed Web of Science ®Google Scholar
• Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54
   PubMed Web of Science ®Google Scholar
• Nilsson BO, Carlsson L, Larsson A, Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001;106:43-9
   PubMed Web of Science ®Google Scholar
• Larsson A, Ronquist G, Wulfing C, et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 2006;24:195-200
   PubMed Web of Science ®Google Scholar
• Bradley SV, Oravecz-Wilson KI, Bougeard G, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005;65:4126-33
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Laxman B, Rhodes DR, et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004;96:834-43
   PubMed Web of Science ®Google Scholar
• Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35
   PubMed Web of Science ®Google Scholar
• Bradford TJ, Wang X, Chinnaiyan AM. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006;24:237-42
   PubMed Web of Science ®Google Scholar
• Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001;10:393,415, x
   PubMedGoogle Scholar
• Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 1999;14:535-41
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Yamanaka K, et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999;39:123-9
   PubMed Web of Science ®Google Scholar
• McCabe NP, Angwafo FF III, Zaher A, et al. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 2000;7:879-82
   PubMed Web of Science ®Google Scholar
• Piironen T, Haese A, Huland H, et al. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 2006;52:838-44
   PubMed Web of Science ®Google Scholar
• Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007;120:1499-504
   PubMed Web of Science ®Google Scholar
• Shariat SF, Roehrborn CG, Mcconnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25:349-55
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10
   PubMed Web of Science ®Google Scholar
• Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-6
   PubMed Web of Science ®Google Scholar
• Shariat SF, Andrews B, Kattan MW, et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58:1008-15
   PubMed Web of Science ®Google Scholar
• Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004;90:2312-6
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005;11:1815-20
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-9
   PubMed Web of Science ®Google Scholar
• Ivanovic V, Melman A, Davis-Joseph B, et al. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med 1995;1:282-4
   PubMed Web of Science ®Google Scholar
• Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7
   PubMed Web of Science ®Google Scholar
• Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64
   PubMed Web of Science ®Google Scholar
• Sinnreich O, Kratzsch J, Reichenbach A, et al. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters. Prostate 2004;61:201-8
   PubMed Web of Science ®Google Scholar
• Shariat SF, Walz J, Roehrborn CG, et al. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 2008;179:1593-7
   PubMed Web of Science ®Google Scholar
• Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9
   PubMed Web of Science ®Google Scholar
• Shariat SF, Walz J, Roehrborn CG, et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 2008;26:1526-31
   PubMed Web of Science ®Google Scholar
• Reeves JR, Xuan JW, Arfanis K, et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005;385:105-14
   PubMed Web of Science ®Google Scholar
• Wu D, Guo Y, Chambers AF, et al. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem 1999;76:71-83
   PubMed Web of Science ®Google Scholar
• Nam RK, Reeves JR, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006;175:1291-7
   PubMed Web of Science ®Google Scholar
• Reeves JR, Dulude H, Panchal C, et al. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006;12:6018-22
   PubMed Web of Science ®Google Scholar
• Girvan AR, Chang P, van Huizen I, et al. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005;65:719-23
   PubMed Web of Science ®Google Scholar
• Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8,15; discussion 15-6
   PubMed Web of Science ®Google Scholar
• Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9
   PubMed Web of Science ®Google Scholar
• de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8
   PubMed Web of Science ®Google Scholar
• Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311,5; discussion 315-6
   PubMed Web of Science ®Google Scholar
• Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-5
   PubMed Web of Science ®Google Scholar
• van Gils MP, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13:939-43
   PubMed Web of Science ®Google Scholar
• Sokoll LJ, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008;389:1-6
   PubMed Web of Science ®Google Scholar
• Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92
   PubMed Web of Science ®Google Scholar
• van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68:1215-22
   PubMed Web of Science ®Google Scholar
• Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804,9; discussion 1809-10
   PubMed Web of Science ®Google Scholar
• Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol Med 2006;12:529-36
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9
   PubMed Web of Science ®Google Scholar
• Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8
   PubMed Web of Science ®Google Scholar
• Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8
   PubMed Web of Science ®Google Scholar
• Laxman B, Morris DS, Yu J, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645-9
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097-106
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52
   PubMed Web of Science ®Google Scholar
• Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 2004;205:181-8
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86
   PubMed Web of Science ®Google Scholar
• Woodson K, Hayes R, Wideroff L, et al. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003;55:199-205
   PubMed Web of Science ®Google Scholar
• Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941-5
   PubMed Web of Science ®Google Scholar
• Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727-30
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003;9:2673-7
   PubMed Web of Science ®Google Scholar
• Gonzalgo ML, Nakayama M, Lee SM, et al. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004;63:414-8
   PubMed Web of Science ®Google Scholar
• Crocitto LE, Korns D, Kretzner L, et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004;64:821-5
   PubMed Web of Science ®Google Scholar
• Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75
   PubMed Web of Science ®Google Scholar
• Roupret M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720-5
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 2001;945:51-8
   PubMed Web of Science ®Google Scholar
• Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58:335-8
   PubMed Web of Science ®Google Scholar
• Malik G, Rojahn E, Ward MD, et al. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression. Prostate 2007;67:1565-75
   PubMed Web of Science ®Google Scholar
• Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43
   PubMed Web of Science ®Google Scholar
• Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14
   PubMed Web of Science ®Google Scholar
• Skytt A, Thysell E, Stattin P, et al. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer 2007;121:615-20
   PubMed Web of Science ®Google Scholar
• McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60
   PubMed Web of Science ®Google Scholar
• Schwamborn K, Krieg RC, Reska M, et al. Identifying prostate carcinoma by MALDI-Imaging. Int J Mol Med 2007;20:155-9
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-83
   PubMed Web of Science ®Google Scholar
• Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-8
   PubMed Web of Science ®Google Scholar
• Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638-44
   PubMed Web of Science ®Google Scholar
• Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9
   PubMed Web of Science ®Google Scholar
• Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-9
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15:1787-93
   PubMed Web of Science ®Google Scholar